Golden State Equity Partners
AXSM icon

Golden State Equity Partners’s Axsome Therapeutics AXSM Stock Holding History

Golden State Equity Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.1K Buy
+82
New +$17.8K ﹤0.01% 1339
2026
Q2 		– Sell
-67
Closed -$11.3K – 454
2026
Q1 		$11.3K Buy
+67
New +$11.6K ﹤0.01% 1262

Other funds holding AXSM

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Alethea Capital Management
Alethea Capital Management Mercer Island, Washington $197M AUM 51.86% 1-Year Est. Return

Golden State Equity Partners's AXSM Position: Q3 2026 in Review

Golden State Equity Partners opened a new position in Axsome Therapeutics (AXSM) in Q3 2026: 82 shares worth $15.1K. The stake represents ﹤0.01% of the portfolio and ranks #1339 among its holdings. This is a return to the name: Golden State Equity Partners previously reported a position in AXSM as recently as Q1 2026.

Golden State Equity Partners first reported a position in AXSM in Q1 2026 and has held it in 2 quarters since. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Golden State Equity Partners held 82 shares of Axsome Therapeutics worth $15.1K as of Q3 2026.
  • Axsome Therapeutics was a new Golden State Equity Partners position in Q3 2026.
  • Axsome Therapeutics made up ﹤0.01% of Golden State Equity Partners's portfolio in Q3 2026, its #1339 holding.
  • Golden State Equity Partners first reported a position in Axsome Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Golden State Equity Partners's 13F filing for Q3 2026, filed 3 Nov 2026.